Abbott’s Dissolving Heart Stent Clears Arteries in Trial
This article is for subscribers only.
Abbott Laboratories’ disappearing stent, inserted to prop open a clogged artery and absorbed by the body over time, performed about as well as the company’s market-leading Xience device in its first scientific trial.
The study showed some early signals of unique benefits and risks from the device, known as Absorb, though patients getting either therapy fared about the same. The findings presented at a conference today in Washington should be reassuring for doctors and patients in Europe, where it has been on the market for the past three years, said investigator Patrick Serruys, head of interventional cardiology at Erasmus University Hospital in the Netherlands.